Market news

CareDx has staged a dramatic turnaround, resolving Medicare risk, returning to profitability, and initiating share buybacks. Read more on CDNA stock here.

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CareDx (CDNA) is up about 14% today after BTIG raised its price target from $60 to $74 and maintained its Buy rating. That’s a big move for a target bump – and there may be even more upside to be had… The detailsBTIG hosted CareDx’s CEO, CFO, and head of investor relations for investor meetings in Boston earlier this week, and came away more bullish: Target raised 23%, from $60 to $74Management sounded confident after the positive resolution of the transplant local coverage determination (this i

CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.

Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.

CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.

CareDx (CDNA) stock has recently drawn attention after a sharp move in its share price. With returns over the past month and past 3 months well into double digits, investors are reassessing expectations. See our latest analysis for CareDx. Looking beyond the past month, CareDx has shown building momentum, with a 30.9% 1 month share price return, a 124.7% 3 month share price return and a 1 year total shareholder return of about 3.8x. The current share price of US$48.61 reflects a market that...

CareDx stock has delivered very strong gains over the past few years, yet the latest valuation checks and current market multiples point to a share price that leans expensive rather than clearly cheap. For investors, that raises the question of how much of the recent share price strength already reflects expectations that are built into the current valuation. CareDx has returned around 4.6x over the past 3 years, which makes any new entry point far more sensitive to how much is already...

CareDx, Healthcare Services Group, Forum Energy Technologies, Amneal Pharmaceuticals and Caterpillar emerge as high-efficiency stocks poised for stronger returns.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Discovery Fund”. A copy of the letter is available to download here. Baron Discovery Fund appreciated by 19.08% (Institutional Shares) in the quarter, underperforming the Russell 2000 Growth Index, which gained 25.71%. This lag was primarily due to a momentum-driven “AI […]

CareDx (CDNA) has surged 300% over the past year, driven by robust technical momentum and strong buy signals. CDNA is rated a “Strong Buy” by several analysts, with consensus price targets suggesting up to 12% further upside. Revenue is projected to...

BRISBANE, Calif., August 07, 2026--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants.

Detailed price information for Regenxbio Inc (RGNX-Q) from The Globe and Mail including charting and trades.

BRISBANE, Calif., July 31, 2026--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company’s newly appointed Executive Advisor, certain stock awards as an inducement material to Mr. McNally’s employment with CareDx.

The diagnostics leader is accelerating the trend toward precision medicine.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform. Total revenue rose to $132 million

CareDx (CDNA) reported Q2 non-GAAP earnings late Thursday of $0.37 per diluted share, up from $0.10

BRISBANE, Calif., July 30, 2026--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026.

CareDx (CDNA) delivered earnings and revenue surprises of +68.18% and +15.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CareDx stock has delivered a very strong 273.8% return over the past three years. However, its current valuation checks and recent share price strength point to a stock that may now be leaning expensive rather than clearly mispriced. Over the last three years, CareDx has returned 273.8%. This puts extra focus on whether the current price still reflects a reasonable balance between potential and risk. The finalization of Medicare coverage for CareDx’s solid organ transplant molecular tests...

CareDx (CDNA) is back in focus after Medicare finalized a Local Coverage Determination for molecular testing in solid organ transplants, confirming reimbursement for the company’s kidney, heart, and lung transplant surveillance portfolio. See our latest analysis for CareDx. The finalized Medicare LCD arrives after a sharp swing in sentiment around CareDx, with a 30 day share price return of 69.21% and a 1 year total shareholder return of 233.45%, even though the 5 year total shareholder...

CareDx, Inc. previously announced that Medicare finalized a Local Coverage Determination for molecular testing to monitor solid organ transplant rejection, affirming coverage for its AlloSure Kidney, AlloMap and AlloSure Heart, and AlloSure Lung surveillance tests with defined testing limits over the first three years post-transplant. This decision removes a key reimbursement uncertainty for CareDx’s core transplant-testing portfolio, clarifying how frequently clinicians can use these...

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BRISBANE, Calif., July 16, 2026--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.

CareDx ($CDNA) shares surge 28% as Medicare finalizes continued coverage for its kidney, heart, and lung transplant tests.

Final Medicare policy supports transplant surveillance portfolioCareDx Inc. (NASDAQ:CDNA) shares climbed 20% on Thursday after the company announced that Medicare had finalized its Local Coverage Determination (LCD) covering molecular testing for solid organ transplant rejection.

CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.